Rapid Abstract Session C: Cancers of the Colon, Rectum, and Anus

Mary Uan-Sian Feng, MD—Chair, University of California, San Francisco

Jeffrey A. Meyerhardt, MD, MPH, FASCO—Chair, Dana-Farber Cancer Institute/ Partners Cancer Care

Abstract 484: A randomized phase III trial of S-1/oxaliplatin (SOX) versus UFT/leucovorin as adjuvant chemotherapy for high-risk stage III colon cancer: The ACTS-CC 02 trial.
First Author: Takao Takahashi, MD, PhD

Conclusions: SOX was not shown to be superior to UFT/LV in pts with high-risk stage III colon cancer. However, the oxaliplatin-based regimen was suggested to be more effective in advanced disease, such as stage IIIC and N2b. Clinical trial information: JapicCTI-101073.

Abstract 485: Circulating tumor cell count from a blood sample for colorectal cancer (CRC) prevention: A 627-patient prospective study.
First Author: Wen-Sy Tsai

Conclusions: To the best of our knowledge, these are the first reported results for a blood test that has high accuracy for adenoma detection, and truly enables colorectal cancer prevention. This test can be administered in the primary care setting and drive high compliance.

Abstract 486: Total neoadjuvant therapy with short course radiation compared to concurrent chemoradiation in rectal cancer.
First Author: William Chapman Jr., MD, MPHS

Conclusions: SC-TNT yielded a pCR rate of 25% and overall recurrence rate of 14.9% among patients with locally advanced rectal cancer. Short course radiation with neoadjuvant multiagent chemotherapy is at least as effective as long-course CRT.

Abstract 487: Immunoscore clinical utility to identify good prognostic colon cancer stage II patients with high-risk clinico-pathological features for whom adjuvant treatment may be avoided.
First Author: Jerome Galon, PhD

Conclusions:

  • Among High-risk untreated St II patients: 69.5% had a High lmmunoscore with SY TTR of 87.4% (95% Cl 83.9-91.0), significantly superior to the SY TTR of the Low lmmunoscore patients (72.2% (95% Cl 65.6-79.6)) (p<0.00001).
  • Among untreated St II patients: the SY TTR observed in the High lmmunoscore High-risk group (87.4%) is statistically similar to the SY TTR observed in the Low-risk group: 89.1% (95% Cl 86.1-92.1) (p=0.42).
  • Within High-risk St II patients, SY TTR in patients with a High lmmunoscore is similar in untreated patients and patients who received adjuvant chemotherapy (SY TTR of 83.4 (95% Cl 77.6-89.9)) (p:0.37).
  • Despite the presence of high-risk clinico-pathological features that usually trigger adjuvant treatment, when not treated with chemotherapy, this retrospective study indlcates that a significant part of these patients (69.5%) with high-lmmunoscore, had a recurrence risk similar to the untreated low-risk patients. This study reinforces lmmunoscore clinical utility to guide adjuvant treatment decisions in Stage II patients.